Trial Profile
Treatment adherence to Ibrutinib in patients with Lymphocytic leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Lymphoid leukaemia
- Focus Therapeutic Use
- 22 Jul 2017 New trial record
- 25 Jun 2017 Results (n=552) assessing treatment adherence with ibrutinib, presented at the 22nd Congress of the European Haematology Association.